Paul Hamlin, Clinical Director of Memorial Sloan Kettering’s Lymphoma Outpatient Unit, describes a clinical trial to better understand factors that increase the risk of chemotherapy side effects in older people undergoing treatment for diffuse large B-cell lymphoma (DLBCL).
The goal of the study is to develop a comprehensive assessment for older people with DLBCL that will help in predicting and therefore preventing chemotherapy-related side effects by customizing the choice of agent used. A number of factors can affect this risk, such as nutritional status, memory capacity, walking ability, and other medical conditions and treatments.
The trial will also evaluate the effectiveness of pre-chemotherapy treatment (low-dose prednisone combined with a targeted therapy to reduce the volume of B cells) in reducing side effects.
If you’re interested in participating in the study, please call 212-639-6143 for information.